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Reply to the Editor:
We appreciate the interest of Sim and col-
leagues in our article describing the im-
plantation of single, isolated skeletal mus-
cle fibers into the heart. We agree that
many important questions need to be an-
swered before further clinical trials of myo-
blast transplantation into the heart.
A major issue is the mechanism by
which skeletal myoblast transplantation
can improve cardiac function. Sim and
colleagues’ suggestion that the improve-
ment in myocardial function is directly
related to the number of myoblasts im-
planted has not been firmly established.
We consider the quality of cells im-
planted to be as important as, or perhaps
even more important than, cell number.1
In addition, only one recent study with
donor cardiac myocytes has attempted to
adequately quantify graft cell survival
with quantitative real-time polymerase
chain reaction, and no direct correlation
between numbers of surviving donor-de-
rived cells and functional improvement
was made in that study.2
It should be noted that the issues re-
garding the adverse effects of prolonged
in vitro culture on skeletal myoblasts are
far from theoretical, as suggested by Sim
and colleagues. There is clear evidence
for the susceptibility to infection, as well
as altered immunogenicity and adverse
effects on myogenicity.3 With respect to
the risk of coronary embolism after cell
transplantation, we have reported that in-
fusion of more than 2 million myoblasts
in a volume of 1mL into the coronary
circulation of the rat heart results in em-
bolization, with edema and cardiac ar-
rest.4
Sim and colleagues suggest that the
functional benefit of myoblast transplanta-
tion is due, at least in an ischemic heart
failure model, to the formation of new mus-
cle (“neomyogenesis”) with “phenotypic
features similar to skeletal and cardiac
muscle.” This statement is not clear, and
such a mechanism would require extensive
functional, electrophysiological, and mo-
lecular characterization.
The relevance of the discordant hu-
man-to-pig xenogenic model cited by
Sim and colleagues is not clear, and it is
unlikely that a significant degree of myo-
blast survival would be seen after graft-
ing with only transient immunosuppres-
sion—although the protocol for this is
not detailed. We find interpretation of the
staining in the figure difficult. With re-
spect to labeling, the promoter driving
reporter lacZ expression is not stated;
thus one cannot be absolutely certain as
to the identity of the stained cells in the
presented figure. The varied distribution
of the X-gal stain is difficult to explain,
and counterstaining with skeletal myo-
sin–specific antibody, as reported in our
own data, would be informative; an ad-
ditional nuclear marker would confirm
the specificity of the stain.
The key findings in our study are that
myogenic precursor cells derived from the
parent fibers appeared to survive, prolifer-
ate, and differentiate within the cardiac mi-
croenvironment. Further, this treatment im-
proved cardiac function in ischemic and
dilated cardiomyopathy models to a degree
that was far beyond what one might expect
for the amount of new muscle formed. We
have proposed at least two possible causes
for this remarkable effect. One is a para-
crine effect resulting in neoangiogenesis,
as shown in our article; the other is the
endogenous protection afforded to the res-
ident satellite cells by the parent fiber. This
latter effect may be important in enhancing
graft cell survival in the most hazardous
acute phase after grafting and may also
deliver satellite cells that have some impor-
tant qualitative differences. We consider
the skeletal muscle fiber system to be
promising, although further studies are
needed to investigate the effects that we
have proposed.
Bari Murtuza
Ken Suzuki
Magdi H. Yacoub
Harefield Hospital Heart Science Centre
Imperial College Faculty of Medicine
London, United Kingdom
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Large cell neuroendocrine
carcinoma of the lung: What we
have to do
To the Editor:
I read with interest the excellent article of
Takei and colleagues1 about large cell neu-
roendocrine carcinoma (LCNC) of the
lung. This series represents the largest ever
published in English language literature.
The family of neuroendocrine tumors of
the lung has recently been the object of
study by several pathologists and surgeons.
The recent World Health Organization
classification criteria2 consider neuroendo-
crine tumors of the lung as a distinct subset
of neoplasm with specific morphologic, ul-
trastructural, immunohistochemical, and
molecular characteristics. Travis and asso-
ciates3 distinguish between typical and
atypical carcinoid, LCNC, and small cell
neuroendocrine carcinoma of the lung. Of
these tumors, LCNCs appear to have an
intermediate biologic behavior between
atypical carcinoid and small cell carcino-
ma.3 LCNCs have a tendency to spread
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